Category Archives: Neurotechnology

Newest Hardware Release Muse S (Gen 2) Uses "Smart Fade" Technology to Sense When You Awaken During The Night and To Automatically Deliver A "Digital Sleeping Pill" To Help Get You Back to Sleep Faster

TORONTO, October 20, 2021--(BUSINESS WIRE)--Interaxon Inc. (Muse), a leading consumer neurotechnology and meditation company, today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005215/en/

Muse today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night. (Photo: Business Wire)

Alongside the launch of the updated Muse S headband, Interaxon is launching an intelligent new kind of EEG-powered sleep experience that is designed to help put you to sleep and guide you back to sleep if youve woken during the night.

Interaxon has been excited to offer this never-before-seen sleep intervention after building on their successful release of sleep content & EEG sleep tracking insights to support healthy sleep habits. A recent 2021 study led by Western University, Cambridge Brain Science, Hatch, and Interaxon that used Muse S EEG-sleep support technology showed a 20% improvement in the Pittsburgh Sleep Quality Index, relative to controls wanting to improve their sleep.

"For many of us, increasingly busy days translate into busy minds at night and restless sleep. While sleep tracking can be helpful to gain insights on trends and changes in your sleep quality, tracking your sleep doesnt provide immediate relief when you need it most," said Walter Greenleaf, Chief Science Officer at Interaxon (Muse). "According to the CDC, more than a third of American adults are not getting enough sleep on a regular basis with less than seven hours per day.1 This innovative new solution can help users get the rest they need to improve their overall wellness with a non-pharmaceutical sleep aid."

Story continues

Digital Sleeping Pills (DSPs)

Muse Digital Sleeping Pills or DSPs are designed to help you through the wind-down process by responding to your brains rhythms and helping you disengage from your busy mind. Muse S detects the natural changes in your brain activity as you fall asleep and uses those changes to gently fade out your audio to cue your brain that its time for sleep. If you wake in the night, Muse S uses the same Smart-Fade technology to automatically fade in the DSP content to guide you back to sleep again.

Sleep content preferences can vary widely from person to person. Some people are looking for a more engaging story to keep their mind from getting stuck in ruminating thoughts, while others may find a story too exciting to fall asleep to and prefer a softer, guided meditation or ambient soundscape. Depending on what type of content helps you fall asleep best, you can select a variety of different DSPs to help you on your journey including all-new:

Original, Classic, and Adventure Sleep Stories that have a voice narration of some of your favorite childhood stories & a variety of new original stories

Ambient Sleep Soundscapes that offer soothing ambient music and harmonized sounds without a voice narrative

Biofeedback Sleep Soundscapes that offer nature sounds and music that respond to biofeedback without a voice narrative

Guided Sleep Meditations that have a meditation teacher guide you through a relaxing sleep meditation

In addition to the advanced EEG technology that Muse is known for, the all-new second-generation Muse S has improved signal quality for increased accuracy and enhanced battery performance with up to 50% reduction in charging time. Additionally, improved fit for a wider range of head sizes has been achieved with the same comfortable, adjustable, and washable fabric band.

Pricing and Availability

Muse S (Gen 2) is now available for $399.99 USD at http://www.choosemuse.com and will be available on Amazon North America starting in 2022. Both first and second-generation Muse S headbands will have access to the new Digital Sleep Pill (DSP) features free of charge with Gen 1 users gaining access in December of 2021.

To unlock Biofeedback+ and unlimited access to 500+ meditations with new content released monthly, you can subscribe to the Muse Premium Subscription for $12.99 USD per month or $94.99 USD per year.

In addition to a rich content library of more than 500 meditations from renowned meditation teachers, unlock access to a variety of relaxation techniques, Go-to-Sleep soundscapes, and in-depth courses with step-by-step instructions, such as The Sleep Basics course by Dr. Shelby Harris, an expert in behavioral sleep medicine. Additionally, youll have access to Biofeedback+ which is designed to allow you to see how your brain and body responds to external content whether it be music in Spotify, Audiobooks, or meditations in Headspace.

Now available at http://www.choosemuse.com.

About Muse by Interaxon Inc.:

At Muse, our team of neuroscientists, meditation teachers, and engineers based out of Toronto who develop state-of-the-art experiences using research-grade EEG technology. Our goal is to help individuals build a rewarding meditation practice and live healthier, happier, more connected lives through human-centered technology. Our award-winning neurofeedback devices, and premium content offering of guided meditations with responsive learning functionality, is designed to help users meditate by providing real-time audio feedback on their meditative state through the Muse companion app. We make the intangible, tangible. Muse is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.

More information about Muse is available at http://www.choosemuse.com.

Milestones were excited about:

More than 500,000 Musers globally

Accessible: Muse is available in four languages, including English, Spanish, French and German

Sessions of meditation with Muse: Over 100 million minutes to date and currently one of the largest brain data (EEG) collections in the world.

Research institutions using Muse: The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and many more.

Meditating with Muse works: Muse has been used in over 200 published studies, including Mayo Clinic who demonstrated meditating with Muse increases quality of life, and decreases stress and fatigue in cancer patients.

Untangle Podcast: With more than 7 million plays, Untangle hosts Patricia Karpas and Ariel Garten interview thought-provoking authors, experts and leaders in areas related to mindfulness, sleep, neuroscience, brain health practices, and more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005215/en/

Contacts

Hanna Thorntonmuse@maxborgesagency.com

Go here to read the rest:

Interaxon Inc. (Muse) Launches the Latest in Non-Pharmaceutical Sleep Support: EEG-Powered Digital Sleeping Pills That Provide Immediate &...

In a biometrics development that might generate some resistance among the AI skeptical, Belgian researchers have demonstrated authentication using brain waves. The waves are like fingerprints or vein patterns unique and detailed.

They used electroencephalography, or EEG, on 15 healthy people and recorded an authentication accuracy rate of 92.6 percent, a false acceptance rate of 2.5 percent and a false rejection rate of 5 percent in one set of tests.

The subjects went through a multitask scheme in which they performed and imagined motor tasks, according to the research teams paper. The researchers used a long short-term memory or LSTM-based recurrent neural network with a bagging or bootstrap aggregation technique to mitigate the limited training data available. Three-second samples of EEG data were fed to the resulting matching algorithm for biometric authentication.

The results above are for the performed tasks, but biometric accuracy rates were similar for imagined and combined tasks.

Each person, wearing a commercial dry-electrode EEG headset, achieved at least 81.3 percent accuracy.

Three participants were tested in a lab, the rest were in their homes. They were in rooms dark except for a computer screen. All electronics were shut off or place in airplane mode to minimize interference.

A year ago, AI vendor Neurotechnology said it had launched a development kit for EEG biometrics.

accuracy | AI | artificial intelligence | authentication | biometrics | biometrics research | brainwave

Follow this link:

Brain wave biometrics yield 93% authentication rate in research - Biometric Update

As multiple coronavirus variants continue to be identified and drug makers seek approval for treatments, the healthcare industry is enjoying the markets attention. This is evident in the Health Care Select Sector SPDR Funds (XLV) 13.5% year-to-date returns. So, amid current market volatility, we think it could be wise to bet on quality healthcare stocks because the sector is defensive and could add stability to ones portfolio.

The prevalence of chronic diseases and an aging population are also expected to increase the need for healthcare solutions. According to a Techtic report, the global healthcare market is expected to reach $11.91 trillion by 2022.

So, we think it could be wise to bet on fundamentally sound healthcare stocks Stryker Corporation (SYK), Boston Scientific Corporation (BSX), and ResMed Inc. (RMD), which are trading below their 52-week highs now.

Click here to checkout our Healthcare Sector Report for 2021

Stryker Corporation (SYK)

Medical technology company SYK in Kalamazoo, Mich., operates through three segments: Orthopaedics; MedSurg; and Neurotechnology and Spine. The company sells its products to several healthcare facilities through company-owned subsidiaries & third-party dealers globally.

On September 7, SYK acquired Gauss Surgical, a medical device company, which developed Triton. Dylan Crotty, president of Strykers Instruments division, said, Our belief is that Triton technology will help improve the industry standards for quantifying blood loss in the labor and delivery department, furthering Strykers commitment to improve safety and outcomes for our caregivers and their patients.

SYKs net sales increased 55.4% year-over-year to $4.29 billion in the second quarter, ended June 30, 2021. Its gross profit came in at $2.77 billion, up 79.1% year-over-year. Its net earnings were $592 million compared to an $83 million loss in the year-ago period. Also, its EPS was $1.55 compared to a $0.22 loss in the previous period.

Analysts expect SYKs revenue and EPS to increase 20.4% and 25.3%, respectively, year-over-year to $17.27 billion and $9.31for its fiscal year 2021. In addition, it has surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 11.9% in price to close yesterdays trading session at $270.86. It is currently trading 3.7% below its 52-week high of $281.16, which it hit on September 9, 2021.

SYKs strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which indicates a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

SYK has a B grade for Growth and Stability. Within the Medical Devices & Equipment industry, it is ranked #45 of 181 stocks. Click here to see the additional POWR Ratings for Value, Momentum, Sentiment, and Quality for SYK.

Boston Scientific Corporation (BSX)

BSX develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The Marlborough, Mass., company operates through three segments: MedSurg; Rhythm and Neuro; and Cardiovascular.

On October 6, BSX announced its agreement to acquire Baylis Medical Company Inc. Mike Mahoney, BSXs Chairman and CEO, said, We believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios.

BSXs net sales increased 53.6% year-over-year to $3.08 billion for its fiscal second quarter, ended June 30, 2021. The companys operating income came in at $262 million, versus a $71 million loss in the prior year. Its gross profit in the quarter was $2.13 billion, up 75.9% from the year-ago period. Also, its EPS came in at $0.12 compared to a $0.11 loss per share in the prior years quarter.

For its fiscal year 2021, analysts expect BSXs revenue to be $12 billion, representing a 21.1% year-over-year rise. The companys EPS is expected to increase 67.7% year-over-year to $1.61 in fiscal 2021. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 21.7% in price to close yesterdays trading session at $44.13. It is currently trading 4.7% below its 52-week high of $46.29, which it hit on August 2, 2021.

BSXs POWR Ratings reflect this promising outlook. The stock has an overall B rating, which equates to a Buy in our POWR Rating system. Also, the stock has an A grade for Growth.

Click here to see BSXs ratings for Value, Momentum, Stability, Sentiment, and Quality as well. Again, BSX is ranked #33 in the Medical Devices & Equipment industry.

ResMed Inc. (RMD)

RMD develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care; and Software as a Service. RMD is headquartered in San Diego, Calif.

On August 16, RMD launched its AirSense 11 PAP Series, advancing digital health in sleep apnea treatment. Jim Hollingshead, the companys president of Sleep and Respiratory Care segment, said AirSense 11s new tailored features along with our myAir patient engagement app help give people the support they need to use PAPthe gold standard for treating sleep apneacomfortably and confidently every night.

RMDs revenue increased 13.7% year-over-year to $876.1 million in its fiscal fourth quarter, ended June 30, 2021. Its income from operations came in at $241.6 million, up 8.2% from the previous period. And its non-GAAP net income was $198.4 million, up 2.6% year-over-year. Also, its non-GAAP EPS came in at $1.35, up 1.5% year-over-year.

For its fiscal year 2022, RMDs revenue and EPS are expected to grow 18.6% and 17.4%, respectively, year-over-year to $3.79 billion and $6.26. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past nine months, the stock has gained 21.1% in price to close yesterdays trading session at $260.16. It is currently trading 13.7% below its 52-week high of $301.34, which it hit on September 9, 2021.

RMDs strong fundamentals are reflected in its POWR ratings. The stock has an overall B rating, which equates to a Buy in our proprietary rating system.

In addition, it has a B grade for Stability, Sentiment, and Quality. RMD is ranked #20 in the Medical Devices & Equipment industry. Click here to see the additional POWR Ratings for RMD (Growth, Value, and Momentum).

Click here to checkout our Healthcare Sector Report for 2021

SYK shares were trading at $273.64 per share on Wednesday afternoon, up $2.78 (+1.03%). Year-to-date, SYK has gained 12.50%, versus a 22.05% rise in the benchmark S&P 500 index during the same period.

Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...

Read the original here:

SYK: 3 Healthcare Stocks to Buy on the Dip - StockNews.com

LUBBOCK, Texas, Oct. 19, 2021 /PRNewswire/ --West Texas patients seeking outpatient knee replacement surgery have a new, high-quality, cost-effective choice for their care at a nationally accredited center that meets the highest standards for patient safety and quality.

Dr. David Shephard announced today the successful completion of West Texas' first outpatient robot-assisted knee replacement surgery at a free-standing ambulatory surgery center (ASC) using the Stryker MAKO surgical robot.

Dr. Shephard is a Johns Hopkins fellowship trained and board-certified orthopedic surgeon, and a partner at Lubbock Sports Medicine. He has performed more than a thousand robot-assisted knee replacements at Covenant Medical Center and Grace Surgical Hospital and welcomed the opportunity to extend this treatment option to a completely new environment.

"For appropriate candidates, an ASC is a safe, convenient, and cost-effective option, and we are proud to be the first center in West Texas to offer patients this choice," stated Dr. Shephard. "Patients who undergo robot-assisted total knee replacement at our center will often go home the same day, at most the next morning. Studies show that recovery at home can be beneficial to the patient, speeding the healing process, and reducing the risk of infection."

The Ambulatory Surgery Center Association notes that "ASCs have transformed the outpatient experience for millions of Americans by providing them with a more convenient alternative to hospital-based outpatient proceduresand done so with a strong track record of quality care and positive patient outcomes," and ASCs save Medicare and patients billions of dollars each year by offering excellent care at lower overall costs.

"The Stryker MAKO robotic platform was selected because of its strong track record of proven results," stated CHPSC Administrator Alfonso del Granado. "And now, for the first time, patients in West Texas have the option to benefit from this innovative technology in an ambulatory surgery center. Too often, patients have not been able to afford the treatment options available at large hospitals. With this new program, we are demonstrating our commitment to offer patients the best care in West Texas."

About Covenant High Plains Surgery Center, LLCCovenant High Plains Surgery Center (CHPSC) operates two freestanding, independent multispecialty ambulatory surgery centers in Lubbock, Texas. Fully accredited by the Accreditation Association for Ambulatory Health Care and by the American Society for Metabolic and Bariatric Surgery, CHPSC was created by the 2015 merger of Covenant SurgiCenter (est. 1986) and High Plains Surgery Center (est. 2006). With 14 operating and procedure rooms and more than a hundred physicians on staff, CHPSC offers the latest treatment options in dermatology, ENT, general surgery, GI, gynecology, neurosurgery, ophthalmology, orthopedics, pain, plastic & reconstructive surgery, podiatry, and urology to patients from Texas, New Mexico, and Oklahoma. For more information, visit http://www.CHPSurgery.com.

About Lubbock Sports Medicine & RehabLubbock Sports Medicine's mission is to provide the very latest treatment options for orthopedic injuries. Their focus is on active people from all walks of life, including recreational and elite level athletes. Their physicians take the time to listen to patients' needs and present them with the treatment options that will help them live the quality of life they desire. More information is available at http://www.LubbockSportsMed.com.

About StrykerStryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at http://www.Stryker.com.

About the Ambulatory Surgery Center AssociationThe Ambulatory Surgery Center Association (ASCA) assists ambulatory surgery centers (ASCs) in delivering safe, high-quality, cost-effective patient care. For more information, visit http://www.ASCAssociation.org.

SOURCE Covenant High Plains Surgery Center

http://www.chpsurgery.com

Continued here:

Covenant High Plains Surgery Center becomes West Texas' only ambulatory surgery center to perform robot-assisted total knee replacement surgery -...

The resumption of the rescheduling of elective surgeries as fewer COVID-19 patients are hospitalized, and an aging population, are driving the demand for medical devices. Investors interest in the medical device stocks is evident in the iShares U.S. Medical Devices ETFs (IHI) 2.5% gains over the past three months and 14.5% year-to-date returns.

The integration of advanced technologies and innovative treatments are expected to drive the medical devices industrys growth. According to a Research and Markets report, the global medical devices market is expected to grow at a 6.1% CAGR to $661 billion by 2026.

Given this backdrop, we think it could be wise to bet on fundamentally strong medical device stocks Stryker Corporation (SYK), Edwards Lifesciences Corporation (EW), Boston Scientific Corporation (BSX), and Zimmer Biomet Holdings, Inc. (ZBH). These stocks are rated Buy in our POWR Ratings system.

Click here to checkout our Healthcare Sector Report for 2021

Stryker Corporation (SYK)

Medical technology company SYK operates through three segments: Orthopaedics; MedSurg; and Neurotechnology and Spine. The Kalamazoo, Mich.-based company sells its products to several healthcare facilities through company-owned subsidiaries and third-party dealers globally.

On September 7, 2021, SYK announced its acquisition of Gauss Surgical, a medical device company that developed Triton. Dylan Crotty, president of Strykers Instruments division, said, Our belief is that Triton technology will help improve the industry standards for quantifying blood loss in the labor and delivery department, furthering Strykers commitment to improve safety and outcomes for our caregivers and their patients.

SYKs net sales increased 55.4% year-over-year to $4.29 billion in the second quarter, ended June 30, 2021. Its gross profit came in at $2.77 billion, up 79.1% year-over-year. Its net earnings were $592 million compared to an $83 million loss in the year-ago period. Also, its EPS was $1.55 versus a $0.22 loss in the previous period.

Analysts expect SYKs revenue and EPS to increase 20.5% and 25.4%, respectively, year-over-year to $17.29 billion and $9.32 for its fiscal year 2021. In addition, it has surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 8.3% in price to close yesterdays trading session at $262.05.

SYKs strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which indicates a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

SYK has a B grade for Growth and Stability. Within the Medical Devices & Equipment industry, it is ranked #44 of 182 stocks. Click here to see the additional POWR Ratings for Value, Momentum, Sentiment, and Quality for SYK.

Edwards Lifesciences Corporation (EW)

EW in Irvine, Calif., provides products and technologies for structural heart disease and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. The company distributes its products through a direct sales force and independent distributors.

On July 29, 2021, Michael A. Mussallem, EWs Chairman and CEO, said, Vaccine adoption in key regions has contributed to an increased number of patients seeking and, most importantly, receiving treatment. This quarter, we were pleased that more than 30,000 patients were treated globally with SAPIEN valves, an indication that more patients are benefiting from our life-changing technologies than ever before.

For its fiscal second quarter, ended June 30, 2021, EWs net sales increased 48.8% year-over-year to $1.38 billion. The companys gross profit increased 51.7% from the same period last year to $1.04 billion. Its operating income came in at $542.1 million compared to a $169.7 million loss in the year-ago period. And its EPS was $0.78, versus a $0.20 loss in the previous period.

EWs revenue is expected to be $5.33 billion in fiscal 2021, representing a 21.4% year-over-year rise. The companys EPS is expected to increase 21.5% year-over-year to $2.26 in the current year. It surpassed the Streets EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 26.4% in price to close yesterdays trading session at $111.09.

Its no surprise that EW has an overall B rating, which equates to a Buy in our proprietary rating system. In addition, it has a B grade for Stability and Quality.

EW is ranked #46 in the Medical Devices & Equipment industry. Click here to see the additional POWR Ratings for EW (Growth, Momentum, Value, and Sentiment).

Boston Scientific Corporation (BSX)

BSX develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The Marlborough, Mass.-based company operates through three segments: MedSurg; Rhythm and Neuro; and Cardiovascular.

On October 6, 2021, BSX agreed to acquire Baylis Medical Company Inc. Mike Mahoney, BSXs Chairman and CEO, said, We believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios.

BSXs net sales increased 53.6% year-over-year to $3.08 billion for its fiscal second quarter, ended June 30, 2021. The companys operating income came in at $262 million, compared to a $71 million loss in the prior year. Its gross profit in the quarter was $2.13 billion, up 75.9% from the year-ago period. And its EPS came in at $0.12 compared to an $0.11 loss per share in the prior years quarter.

For its fiscal year 2021, analysts expect BSXs revenue to be $12 billion, representing a 21.1% year-over-year rise. The companys EPS is expected to increase 67.7% year-over-year to $1.61 in its fiscal year 2021. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 17.8% in price to close yesterdays trading session at $42.80.

BSXs POWR Ratings reflect this promising outlook. The stock has an overall B rating, which equates to a Buy in our POWR Rating system. Also, the stock has an A grade for Growth.

Click here to see BSXs ratings for Value, Momentum, Stability, Sentiment, and Quality as well. Again, BSX is ranked #33 in the Medical Devices & Equipment industry.

Zimmer Biomet Holdings, Inc. (ZBH)

Warsaw, Ind.-based ZBH, together with its subsidiaries, designs, manufactures and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

On August 31, 2021, Robert Kraal, Vice President and General Manager, Connected Health at ZBH, said, The introduction of mymobility with Apple Watch underscores Zimmer Biomets commitment to evaluating the real-world clinical benefits of a remote care management platform after orthopedic surgery. These four analyses, utilizing interim data from the ongoing mymobility Clinical Study, suggest that mymobility with Apple Watch may be a viable option to help healthcare professionals monitor how a patient is progressing after surgery and remotely manage rehabilitation regimens to optimize recovery.

ZBHs net sales increased 65.3% year-over-year to $2.03 billion in the second quarter, which ended June 30, 2021. Its operating profit came in at $220.50 million compared to a $171.70 million loss in the previous period. Furthermore, its net earnings were $141.90 million, versus a $206.6 million loss in the year-ago period. Also, its EPS came in at $0.67, compared to a $1 loss in the same period.

For its fiscal year 2021, ZBHs revenue and EPS are expected to grow 15% and 36.9%, respectively, year-over-year to $8.08 billion and $7.76. It surpassed the consensus EPS estimates in each of the trailing four quarters. The stock has gained 9.7% in price since hitting its 52-week low of $130.05 on October 30, 2020, to close yesterdays trading session at $144.97.

ZBHs strong fundamentals are reflected in its POWR ratings. The stock has an overall B rating, which equates to a Buy in our proprietary rating system.

In addition, it has an A grade for Growth, and a B grade for Value. ZBH is ranked #51 in the Medical Devices & Equipment industry. Click here to see the additional POWR Ratings for ZBH (Momentum, Stability, Sentiment, and Quality).

Click here to checkout our Healthcare Sector Report for 2021

SYK shares were trading at $270.13 per share on Tuesday morning, up $8.08 (+3.08%). Year-to-date, SYK has gained 11.06%, versus a 21.54% rise in the benchmark S&P 500 index during the same period.

Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...

More here:

SYK: 4 Medical Device Stocks Rated 'Buy' in the POWR Ratings - StockNews.com

SyncThink, a neurotechnology company and developer of the EYE-SYNC technology, has received clearance from the Food and Drug Administration (FDA) for the EYE-SYNC technology as an aid to concussion, or mild Traumatic Brain Injury (mTBI) Diagnosis.

EYE-SYNC previously received Breakthrough Device Designation from the FDA in 2019, following the initial clearance and commercialisation of the technology platform in 2017.

SyncThink founder and Stanford University professor Jam Ghajar, MD, PhD, said: After a decade of clinical research, 30 publications, and 16 patents, we are pleased to formally extend EYE-SYNCs indications to the many providers who will benefit from rapid, objective diagnostic technology. Concussion is a complex condition and a challenge for many clinicians to manage, so we hope that by offering highly accurate diagnostic tools and proven algorithms, we will help providers and their patients identify the most effective and appropriate treatment.

In support of the application, SyncThink enrolled 1,655 pediatric and adult subjects into a clinical study that collected comprehensive patient and concussion related data for over one year. Utilising this information, SyncThink implemented proprietary algorithms and deep learning models to identify a positive or negative indication of concussion. The study showed that EYE-SYNC demonstrated sensitivity above 82% and specificity above 93%, thereby providing clinicians with significant and actionable data when evaluating individuals with concussion.

SyncThink chief clinical officer Scott Anderson, said: "The outcome of this study very clearly shows the effectiveness of our technology at detecting concussion, and definitively demonstrates the clinical utility of EYE-SYNC. It also shows that the future of concussion diagnosis is no longer purely symptom based, but that of a technology driven multi-modal approach.

The EYE-SYNC technology utilises a series of 60 second eye tracking assessments, neurocognitive batteries, symptom inventories, and standardised patient inventories to identify the type and severity of dysfunction after concussion. The platform generates customisable and interpretive reports that support clinical decision making and offers visual and vestibular therapies to remedy deficits and monitor improvement over time.

Original post:

SyncThink receives further FDA clearance for concussion aid - Med-Tech Innovation

Face Recognition Market Research Report by Type (Artificial Neural Networks, Classical Face Recognition Algorithms, and D?based Face Recognition), by Computing (Cloud Computing and Edge Computing), by Vertical, by Application, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

New York, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Face Recognition Market Research Report by Type, by Computing, by Vertical, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06169309/?utm_source=GNW

The Global Face Recognition Market size was estimated at USD 4,178.26 million in 2020 and expected to reach USD 5,007.90 million in 2021, at a CAGR 20.19% to reach USD 12,598.07 million by 2026.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Face Recognition to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Artificial Neural Networks, Classical Face Recognition Algorithms, D?based Face Recognition, Face Descriptor?based Methods, and Video?based Recognition.

Based on Computing, the market was studied across Cloud Computing and Edge Computing.

Based on Vertical, the market was studied across Automotive & Transportation, BFSI, Education, Energy & Utilities, Government & Defense, Healthcare, Manufacturing, Consumer Goods & Retail, and Telecommunications & IT.

Based on Application, the market was studied across Access Control, Attendance Tracking & Monitoring, Emotion Recognition, Law Enforcement, Robotics, eLearning, Advertising, and Payment.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Face Recognition Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitors strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Face Recognition Market, including Animetrics, AnyVision, Aware, Inc., Ayonix Corporation, Clarifai, Cognitec Systems GmbH, Daon, DeepGlint, FaceFirst, Inc., Gemalto NV, id3 Technologies, IDEMIA, Innovatrics, Megvii, NEC Corporation, Neurotechnology, NVISO SA, SenseTime, StereoVision Imaging, Inc., Techno Brain Group, Visage Technologies, XJERA LABS, XRVision Pte. Ltd., Yitu Technology, and ZOLOZ CO., LTD..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Face Recognition Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Face Recognition Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Face Recognition Market?4. What is the competitive strategic window for opportunities in the Global Face Recognition Market?5. What are the technology trends and regulatory frameworks in the Global Face Recognition Market?6. What is the market share of the leading vendors in the Global Face Recognition Market?7. What modes and strategic moves are considered suitable for entering the Global Face Recognition Market?Read the full report: https://www.reportlinker.com/p06169309/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

View original post here:

Face Recognition Market Research Report by Type, by Computing, by Vertical, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of...

Researchers in Graz control robots with their thoughts

The team at TU Graz made a significant breakthrough in neuroprosthetics using thoughts and a non-neurochip method to control robotic arms

Yesterday, the Graz University of Technology (TU Graz) reported a major breakthrough in neurotechnology for the first time test subjects were able to non-invasively control a robotic arm just by thinking about it. The experiments were done in real-time and the subjects did not use implants or neural chips, but a simple EEG cap, measuring their brain activity.

This research holds great potential for paraplegics precisely because it is non-invasive. The neuroprosthetics uses a technology called Brain-Computer Interfaces (BICs) to measure brain activity and concert that to electrical signals.

According to Gernot Mller-Putz, head of the Institute of Neurotechnology in TU Graz explained that the mere idea of movement triggers a measurable change in brain activity. What researchers needed to do was pinpoint the specific change and relate that to a specific movement.

It also turns out that hand-eye coordination is key to fluid precise motions. Mller-Putz was quoted in a press release explaining that "itis important that users are allowed to use their eyes to follow the trajectory of the robotic arm. The visual information helps to capture the intention to move. The interfering signals from the eye itself, however, have to be calculated from the electrical activity.

The BIC also has a built-in error detection system. Essentially, the interface measures, recognises and corrects errors based on brain activity. Once it has detected an error it either corrects the motion or goes back into the starting position.

The test subjects, participating in the trials were paraplegic and according to Mller-Putz, they were able to replicate the successful trial runs several times.

The researchers went a step further and implemented a kinetic feedback system to go with everything else. What this means is that a subject can feel the movement of the robotic arm as if it were attached to their body. This is done with the help of vibration transmitters, stuck to the skin on the shoulder blade. Theoretically, this means that it is possible for someone who is completely disabled to feel movement again.

Furthermore, Mller-Putz and the team have decided to set the bar for the future even higher, as one of their distant goals is to find applications for the technology in the neck area. For now, however, their immediate pursuit is to decode brain activity even better and perfect the movement of the arm.

Here is the original post:

Researchers in Graz control robots with their thoughts - TheMayor.EU

The Global Face Recognition Software Market report provides internal and external analysis of global market patterns, large-scale financial pointers, and control aspects along with market attractiveness according to sections. The report further maps the characteristic findings of various market aspects to market sections and geography. The report is a point-by-point awareness of several perspectives, including the rate of development, recent advances, and various procedures implemented by the key momentum market players. This report depends on an aggregate investigation of information obtained through mandatory and secondary examinations. It Face Recognition Software provides an orderly way to deal with current and impending market conditions.

The business intelligence report on Face Recognition Software market attempts to clearly inform readers about critical factors such as key trends, primary growth drivers, challenges, and lucrative prospects during 2021-2026.

As per expert analysts, the industry is anticipated to amass notable returns over the forecast duration, recording at a CAGR of XX% throughout.

Request Sample Copy of this Report @ https://www.nwdiamondnotes.com/request-sample/25586

The report casts light on the various segments of the market and recognizes the areas that possess robust income-generating potential. Moreover, it assists key players, new entrants, and other stakeholders in gauging the degree of competitiveness in this domain and accordingly draft strategies that promise strong returns in the ensuing years.

Key highlights of the Face Recognition Software market report

Face Recognition Software market segments included in the report:

Geographical bifurcation: North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Product types: Holistic Matching Method , feature-based Method , Skin Texture Analysis , Hybrid Types and Other

Application spectrum: Corporate & Residential Security , Public Transport , Entertainment Software , Public Security & Justice , Self-service Equipment , Attendance & Conference , Financial Services and Other

Competitive dashboard: Aware (US) , BioID (DE) , Idemia (FR) , Leidos (US) , Visage Technologies (SE) , Cloudwalk (CN) , M2SYS (US) , Gemalto (NZ) , StereoVision Imaging (US) , Cognitec Systems (GE) , HID Global (US) , NEC (JP) , NVISO (BE) , Daon (US) , MEGVII (CN) , Ayonix Face Technologies (IN) , Innovatrics (SK) , HYPR (US) , Fujitsu (JP) , Kairos (US) , Animetrics (US) , id3 Technologies (FR) , Smilepass (GB) , Techno Brain (SA) , Neurotechnology (LT) , Fulcrum Biometrics (US) , FaceFirst (US) and Certibio (BR

Major Findings of the Face Recognition Software Market Report Include:

Why should you buy this Industrial Face Recognition Software Market report?

Request Customization on This Report @ https://www.nwdiamondnotes.com/request-for-customization/25586

More here:

Face Recognition Software market to showcase strong CAGR between 2026 and 2026 - Northwest Diamond Notes

The Global Neural Control Market from 2021 to 2027 primary research analysis, first published by MarketsandResearch.biz, was created with a fantastic blend of operating characteristics, inventive solutions, feasible solutions, and cutting-edge technology to provide a better user experience. The Neural Control market report contains marketing surveys, segment market share, regional presence, strategic plans, advancements, expansions, and technical developments, as well as a portfolio and performance comparison of the economys foremost companies.

The Neural Control marketplace research also includes a feasibility analysis of all markets in the region, calculated based on their market size, growth rate, and attractiveness to present and prospective opportunists to forecast the future market growth.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/213657

The market has been reduced depending on

Hardware, Software

The shrinking of the market due to the presence of dominant players:

MIT, Hebrew university, Haier, Neurotechnology

Market share, dominating segments and geographical data are all examined in detail in a comprehensive report.

The market reduction based on

Hospital, Research

Through strategic analysis, micro and macro market trends, pricing analysis, and a full assessment of market circumstances, the Neural Control Market research report keep a close eye on crucial competitors.

The market has been reduced based on region:

North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/213657/global-neural-control-market-2021-by-company-regions-type-and-application-forecast-to-2026

Way to gather a few of the reports significant advantages:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.biz

Read the original here:

Global Neural Control Market Executive Summary and Analysis by Top Players 2021-2027: MIT, Hebrew university, Haier, Neurotechnology Bulk Solids...